FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100023607> ?p ?o ?g. }

• W2100023607 endingPage "896" @default.
• W2100023607 startingPage "893" @default.
• W2100023607 abstract "<h2>Abstract</h2> To evaluate the effect of pravastatin on progression of coronary atherosclerosis in normocholesterolemic patients with coronary artery disease (CAD), 90 patients with CAD and serum cholesterol levels of 160 to 220 mg/dl were randomized into a pravastatin (10 mg/day) group (n = 45) and control group (n = 45) in a 2-year study. The proportions of patients with progression (an increase of ≥15% in percent stenosis) and regression (a decrease of ≥15% in percent stenosis) of coronary atherosclerosis were compared between the 2 groups. Of 90 patients, 80 (89%) had a final angiogram: the pravastatin (n = 39) and control group (n = 41). Percent changes in total cholesterol, low-density lipoprotein cholesterol, and apoprotein B levels were significantly greater in the pravastatin group than in the control group (total cholesterol −11 ± 12% vs 3 ± 15%, p <0.01; low-density lipoprotein cholesterol −18 ± 16% vs 4 ± 21%, p <0.01; apoprotein B −5 ± 20% vs 6 ± 20%, p <0.05). The proportion of patients with progression of coronary atherosclerosis was significantly smaller in the pravastatin group than in the control group (21% vs 49%, p <0.05). The proportion of patients with disease regression did not differ in the 2 groups (3% vs 2%, p=NS). In conclusion, this study indicates that cholesterol-lowering therapy with pravastatin can prevent the progression of coronary atherosclerosis even in normocholesterolemic patients with established CAD. To evaluate the effect of pravastatin on progression of coronary atherosclerosis in normocholesterolemic patients with coronary artery disease (CAD), 90 patients with CAD and serum cholesterol levels of 160 to 220 mg/dl were randomized into a 2-year study: the pravastatin (10 mg/day) group (n = 45) and the control group (n = 45). Results of this study indicate that cholesterol-lowering therapy with pravastatin can prevent the progression of coronary atherosclerosis stenosis even in normocholesterolemic patients with established CAD." @default.
• W2100023607 created "2016-06-24" @default.
• W2100023607 creator A5005634038 @default.
• W2100023607 creator A5048003057 @default.
• W2100023607 creator A5073355813 @default.
• W2100023607 date "1997-04-01" @default.
• W2100023607 modified "2023-10-17" @default.
• W2100023607 title "Effect of Pravastatin (10 mg/day) on Progression of Coronary Atherosclerosis in Patients With Serum Total Cholesterol Levels from 160 to 220 mg/dl and Angiographically Documented Coronary Artery Disease" @default.
• W2100023607 cites W1966817707 @default.
• W2100023607 cites W1971261277 @default.
• W2100023607 cites W1996447072 @default.
• W2100023607 cites W2003307830 @default.
• W2100023607 cites W2005786831 @default.
• W2100023607 cites W2015834051 @default.
• W2100023607 cites W2029833995 @default.
• W2100023607 cites W2053235682 @default.
• W2100023607 cites W2067535380 @default.
• W2100023607 cites W2089241314 @default.
• W2100023607 cites W2096190290 @default.
• W2100023607 cites W2108668893 @default.
• W2100023607 cites W2116404316 @default.
• W2100023607 cites W2120860913 @default.
• W2100023607 cites W2131275408 @default.
• W2100023607 cites W2132942256 @default.
• W2100023607 cites W2145799136 @default.
• W2100023607 cites W2315618879 @default.
• W2100023607 cites W2324712847 @default.
• W2100023607 cites W2331959986 @default.
• W2100023607 cites W4236017105 @default.
• W2100023607 doi "https://doi.org/10.1016/s0002-9149(97)00010-6" @default.
• W2100023607 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9104901" @default.
• W2100023607 hasPublicationYear "1997" @default.
• W2100023607 type Work @default.
• W2100023607 sameAs 2100023607 @default.
• W2100023607 citedByCount "32" @default.
• W2100023607 countsByYear W21000236072015 @default.
• W2100023607 crossrefType "journal-article" @default.
• W2100023607 hasAuthorship W2100023607A5005634038 @default.
• W2100023607 hasAuthorship W2100023607A5048003057 @default.
• W2100023607 hasAuthorship W2100023607A5073355813 @default.
• W2100023607 hasConcept C126322002 @default.
• W2100023607 hasConcept C164705383 @default.
• W2100023607 hasConcept C2778163477 @default.
• W2100023607 hasConcept C2778213512 @default.
• W2100023607 hasConcept C2779519902 @default.
• W2100023607 hasConcept C2780007028 @default.
• W2100023607 hasConcept C2991716557 @default.
• W2100023607 hasConcept C71924100 @default.
• W2100023607 hasConceptScore W2100023607C126322002 @default.
• W2100023607 hasConceptScore W2100023607C164705383 @default.
• W2100023607 hasConceptScore W2100023607C2778163477 @default.
• W2100023607 hasConceptScore W2100023607C2778213512 @default.
• W2100023607 hasConceptScore W2100023607C2779519902 @default.
• W2100023607 hasConceptScore W2100023607C2780007028 @default.
• W2100023607 hasConceptScore W2100023607C2991716557 @default.
• W2100023607 hasConceptScore W2100023607C71924100 @default.
• W2100023607 hasIssue "7" @default.
• W2100023607 hasLocation W21000236071 @default.
• W2100023607 hasLocation W21000236072 @default.
• W2100023607 hasOpenAccess W2100023607 @default.
• W2100023607 hasPrimaryLocation W21000236071 @default.
• W2100023607 hasRelatedWork W1973590076 @default.
• W2100023607 hasRelatedWork W2011268107 @default.
• W2100023607 hasRelatedWork W2041956434 @default.
• W2100023607 hasRelatedWork W2100023607 @default.
• W2100023607 hasRelatedWork W2109916393 @default.
• W2100023607 hasRelatedWork W2319909300 @default.
• W2100023607 hasRelatedWork W2387394917 @default.
• W2100023607 hasRelatedWork W2888906357 @default.
• W2100023607 hasRelatedWork W3141700921 @default.
• W2100023607 hasRelatedWork W4280603515 @default.
• W2100023607 hasVolume "79" @default.
• W2100023607 isParatext "false" @default.
• W2100023607 isRetracted "false" @default.
• W2100023607 magId "2100023607" @default.
• W2100023607 workType "article" @default.